WARFARIN VS DOACS IN A REAL-WORLD DATA

被引：0
作者：
Carmi, O. [1 ]
Madjar, T. [1 ]
Hornik-Lurie, T. [2 ]
机构：
[1] Meir Med Ctr, Rheumatol, Kefar Sava, Israel
[2] Meir Med Ctr, Stat, Kefar Sava, Israel
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Real-world evidence; Anti-phospholipid syndrome;
D O I：
10.1136/annrheumdis-2023-eular.6069
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1157
引用
收藏
页码：910 / 910
页数：1
相关论文
共 2 条
  • [1] Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure
    Pengo, Vittorio
    Hoxha, Ariela
    Andreoli, Laura
    Tincani, Angela
    Silvestri, Elena
    Prisco, Domenico
    Fierro, Tiziana
    Gresele, Paolo
    Cafolla, Arturo
    De Micheli, Valeria
    Ghirarduzzi, Angelo
    Tosetto, Alberto
    Falanga, Anna
    Martinelli, Ida
    Testa, Sophie
    Barcellona, Doris
    Gerosa, Maria
    Denas, Gentian
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (02) : 531 - 535
  • [2] Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS)
    Woller, Scott C.
    Stevens, Scott M.
    Kaplan, David A.
    Branch, D. Ware
    Aston, Valerie T.
    Wilson, Emily L.
    Gallo, Heather M.
    Johnson, Eric G.
    Rondina, Matthew T.
    Lloyd, James F.
    Evans, R. Scott
    Elliott, C. Gregory
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2016, 22 (03) : 239 - 247
1